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ABSTRACT  At sites of blood vessel injury, platelets release numerous substances that may have 
biological  activities influencing  cellular  responses. In  this study we examined  separately  the 
chemotactic  activity for  fibroblasts  of  three  highly  purified  proteins  obtained  from  platelet 
alpha  granules:  platelet factor 4  (PF4), platelet-derived  growth  factor  (PDGF),  and  /3-throm- 
boglobulin  (BTG). We  observed  that  each  of  these  proteins  was  strongly  chemotactic  for 
fibroblasts, with maximum chemotactic activity in each instance comparable  to that observed 
with an  optimal  concentration  of  the control  chemotactic  protein,  plasma  fibronectin.  Each 
protein was active at very low concentrations. The  peak chemotactic activities of PF4, PDGF, 
and  BTG occurred  at 200 ng/ml, 30 ng/ml,  and 6 ng/ml,  respectively. Specificity of fibroblast 
chemotaxis to individual platelet proteins was provided by finding that anti-PF4 immunoglob- 
ulin  blocked  the  chemotactic  activity of  PF4 without  affecting  the  chemotactic  activity of 
PDGF, while anti-PDGF immunoglobulin  blocked  the activity of  PDGF but did  not alter the 
capacity of  PF4 to  promote  fibroblast  chemotaxis. These results  suggest  that  in  vivo several 
alpha granule  proteins released from  platelets may affect wound  healing by causing directed 
fibroblast migration. 
Apart from an essential role in hemostasis, platelets appear to 
be important for inflammation (1). The mechanisms by which 
platelets mediate inflammation have not been well understood. 
To help determine whether platelets might influence inflam- 
mation by inducing directed cell migration  of inflammatory 
cells to sites of  injury, we undertook to examine the chemotactic 
activities of highly purified platelet secretory proteins for neu- 
trophils and monocytes. Platelet factor 4 (PF4) was shown to 
be a potent chemotactic agent for human monocytes and for 
human neutrophils, at concentrations of PF4 present in normal 
human  serum  and  thus  at  concentrations present  at  sites  of 
injury (2). Subsequently, we reported that the platelet-derived 
growth factor (PDGF) purified to homogeneity is highly active 
as a chemoattractant for human inflammatory cells  (3). Opti- 
mal PDGF concentrations for chemotaxis for monocytes and 
neutrophils were 20 ng/ml and  1 ng/ml, respectively. Coinci- 
dent with these studies, Grotendorst et al. (4) and Seppa et al. 
(5)  reported  that  PDGF  is  chemotactic  for fibroblasts  and 
smooth muscle  cells,  and  suggested  that  PDGF  may be  in- 
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volved in wound healing through effects upon fibroblast move- 
ment. 
The present report extends the observations concerning the 
activity of platelet proteins upon cell migration by establishing 
that PF4 and another platelet alpha-granule protein, B-throm- 
boglobulin (BTG), are highly chemotactic for fibroblasts. The 
results provide additional  information in support  of the  hy- 
pothesis that platelets participate in inflammation and wound 
repair. 
MATERIALS  AND  METHODS 
PF4, PDGF, and BTG were purified from outdated, frozen platelet packs using 
procedures previously reported  (6-8).  Both PFa and BTG  migrated as single 
homogeneous bands in SDS  PAGE (6,  8).  BTG  was established as pure also 
using N-terminal amino acid analysis. PDGF  was resolved into two separate 
homogeneous species, PDGF I and PDGF II (7),  by SDS PAGE; each protein 
species was tested separately for chemotactic activity. Fibronectin, purified from 
human plasma (a gift of Dr. John A. McDonald, Washington University and 
The Jewish Hospital of St. Louis), was used as a positive control. 
Fibroblasts:  Fibroblasts from human skin and bovine nuchal ligament 
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Basic Cancer Research, Washington University School of Medicine, St.  Louis, 
MO),  as  previously described (9).  Confluent  fibroblasts (2-6  passages) were 
detached by exposure to 0.25% (wt/vol) trypsin and 0.1% (wt/vol) ethylenedia- 
minetetraacetic acid (Sigma Chemical Co., St. Louis, MO) in phosphate-buffered 
saline for  3  rain at  37°C  before  use in  chemotaxis assays. The  trypsin  was 
promptly inactivated by dilution into a  5x  volume of fresh culture medium 
containing 10% (vol/vol) fetal bovine serum (KC Biological, Inc., Lenexa, KS). 
To minimize the potential effects of platelet-derived factors contained in the fetal 
bovine serum included in the culture medium, the medium was not changed for 
48 h before the cells were harvested. 
Chemotaxis  As5ay5:  Assays of fibroblast chemotaxis were performed 
in triplicate in a multi-blind well apparatus by the method recently reported (9). 
Each  well of the  apparatus  was separated into two compartments by a pair of 
micropore membranes, an 8-#m micropore membrane (Nucleopore Corp., Pleas- 
anton, CA) overlying  a 0.45-/tm micropore membrane (Millipore Corp., Bedford, 
MA). To obtain attachment and spreading of the fibroblasts  to the membranes, 
the membranes were pretreated with poly-L-lysine  (P-1886,  Sigma Chemical Co., 
St.  Louis, MO). The lower compartment of each well was filled with 240 gl of 
solution to be assayed and the upper compartment was filled with 360 gl of a cell 
suspension containing 1.2 x  l0  s cells per ml. After 6 h of incubation at 37°C the 
chambers were disassembled and the membranes stained with hematoxylin. To 
quantify cell migration, 5  high-power (x  400)  fields (hpf)  were counted per 
membrane pair. In every experiment negative controls were run in parallel. These 
controls, consisting of wells in which the lower compartment contained medium 
only, yielded -20 ceils per hpf. The cell migration in test chambers was corrected 
by subtracting  the number of cells in the corresponding control assays. Accord- 
ingly, the results are reported as net cell migration. 
In some experiments, rabbit anti-PF4  IgG or  rabbit  anti-PDGF  IgG  was 
incubated for 60 min at 37°C with either PF4 or PDGF and then the mixture 
was assayed for chemotactic  activity.  In  these  experiments, in addition to the 
usual negative controls, additional controls of IgG with medium in the lower 
compartment were also included. The IgG were established  as monospecific by 
immunodiffusion analysis against whole platelet lysates and against  the appro- 
priate purified protein. 
RESULTS 
Both  BTG  and  PF4  were  observed  to  promote  fibroblast 
migration, with the optimal cell migration at 6 ng/ml and 200 
ng/ml,  respectively  (Fig.  1A  and  B).  The  effects  of  these 
proteins upon fibroblast migration were established  as chem- 
otactic, since cell movement was little above background when 
the assay chambers were prepared so that the concentration of 
the test protein was either the same in both compartments, or 
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FIGURE  1  Bovine  ligament  fibroblast  migration  in  response  to  B- 
thrombogiobulin  (A) and PF4 (B). Mean and SE of triplicate obser- 
vations. 
high  in  the  upper  compartment.  Maximum  chemotactic  re- 
sponsiveness of fibroblasts to PF4 and to BTG was comparable 
to  the  maximum  chemotactic  response  induced  by  1 gg/ml 
plasma fibronectin (-35 net cells per hpf). 
The  chemotactic  activity  of homogeneous  preparations  of 
PDGF  II  for  fibroblasts  was  then  tested.  Table  I  presents 
results  of examining various concentrations  of PDGF  in the 
upper and lower chambers  of the in vitro chemotactic assay 
("checkerboard analysis"). PDGF is established as chemotactic 
for fibroblasts  in this assay.  Maximal chemotactic activity of 
PDGF occurred at 30 ng/ml, approximately the Ka of PDGF 
for fibroblasts  (10).  The  activity of PDGF  I  was tested  also 
and found to be similar to that of PDGF II. 
Fig. 2, depicting the cell migration of human skin fibroblasts 
in  comparison  to  bovine  ligament  fibroblasts,  indicates  that 
PDGF  has effects  on both types of fibroblasts;  the  dose re- 
sponse curves for both cell types are similar although human 
cells appear t_o be quantitatively less responsive. We previously 
observed a similar difference between chemotactic responses of 
human and bovine cells, using tropoelastin and elastin derived 
peptides as chemoattractants (9). 
Rabbit  immunoglobulins  raised  against  PF4  and  PDGF 
were used to help establish  the specificity of the chemotactic 
responses of fibroblasts to the platelet proteins. The chemotac- 
tic  activity of PF4 for fibroblasts  was abolished by anti-PF4 
IgG, but was unaffected by anti-PDGF  IgG; reciprocally, the 
chemotactic  activity of PDGF  was  abolished  by anti-PDGF 
IgG but unaffected by anti-PF4 IgG (Fig. 3A and B). In these 
experiments,  in  which  the  same  batches  of bovine  ligament 
fibroblasts  were  tested  simultaneously  with  either  PF4  or 
PDGF,  as shown, the peak chemotactic activity to PF4 fully 
equaled the peak chemotactic activity of PDGF, but there is a 
marked difference  between  the  concentration  optimums and 
the  concentration  ranges  over  which  PF4  and  PDGF  are 
effective.  PDGF activity, maximum at 30 ng/ml, is expressed 
over a  1,000-fold range of concentration (0.3-300 rig) whereas 
the activity of PF4, maximal at 200 ng/ml, is expressed over a 
relatively narrow,  10-fold concentration range (50-500 rig). 
TABLE  I 





PDGF, upper compartment, ng/ml 
0  3  15  30 
ng/ml 
3  17 ±  0.5*  5 ±  0.4  0 ±  0.5  4 ±  0.6 
15  29 ±  0.6  13 ±  0.6  6 ±  0.4  2 ±  0.4 
30  52 +  0.9  42 +  0.6  8 ±  0.8  3 ±  0.3 
* Cells/hpf +_ SEM, n =  15 
FIGURE  2  The  migration 
of fibroblasts to PDGF. Bo- 
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FIGURE  3  Bovine  ligament  fibro- 
blast  migration to  PF4 and  PDGF  ~  ,~ 
which  have  been  preincubated  <  ,- 
with (A) anti-PF4 immunoglobulin  ~ 
(PF4 Ab)  or (B)  anti-PDGF  immu- 
noglobulin (PDGF Ab).  (A)  PDGF,  ~ 
(0);  PDGF plus  PF4 Ab,  (O); PF4,  O z 
(A); PF4 plus PF4Ab, (A). (B) PDGF, 
(0); PDGF plus PDGF Ab, (O); PF4,  u 
(A);  PF4 plus  PDGF Ab,  (A).  See 
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DISCUSSION 
When blood vessels are injured, circulating platelets adhere to 
exposed collagen and  to the subendothelial basement mem- 
brane. Aggregation of adhered platelets follows and the plate- 
lets involved release  the  contents  of their alpha  and  dense 
granules (11). In addition to fibrinogen, fibronectin, and other 
proteins also found in plasma, three platelet-specific, alpha- 
granule proteins, PF4, PDGF, and BTG, are released (12). The 
present  experimental  data  demonstrate  that  each  of  these 
unique alpha-granule proteins is a strong chemotactic agent for 
fibroblasts. Thus, platelet-specific secretory proteins have the 
potential to be highly important mediators of fibroblast migra- 
tion into injured areas. Other potentially important mediators 
of fibroblast migration include lymphokines, a  complement- 
related  component,  collagen,  fibronectin,  tropoelastin,  and 
elastin-derived peptides (9,  13-16). 
PF4  was  the  first  platelet-specific, alpha-granule  protein 
shown to be active in chemotaxis of inflammatory ceils, sug- 
gesting a  vital role for platelets as effector cells in initiating 
major events of inflammation and repair (3). Additional sup- 
port favoring a role of PF4 in vivo in mediating chemotaxis of 
inflammatory ceils was  obtained  by the  demonstration  that 
PF4 was active in chemotaxis at concentrations found in human 
serum (17).  In contrast, the concentration of PF4 resulting in 
maximum fibroblast chemotactic activity is less than one-tenth 
that required for optimal chemotaxis of inflammatory cells-- 
the concentration also found in human serum. This differential 
in PF4 concentration for chemotactic activity between inflam- 
matory cells and fibroblasts may have relevance to the types of 
responses initiated by platelets. High-level, acute injury with 
maj or platelet release provides concentrations of PF4 favoring 
inflammation whereas low-level, chronic release may mediate 
fibroblastic ingress. Also, optimal chemotactic concentrations 
for monocytes and neutrophils are found at the immediate site 
of injury, where monocytes and neutrophils are to be found; 
the substantially lower optimal concentrations of PF4 required 
for attracting fibroblasts are consistent with the lower concen- 
trations of PF4 found as the  distance is increased from the 
immediate site of injury to the subendothelial site of focus of 
fibroblasts in vivo. The differences in optimal concentrations 
of PF4 required for cell migration of monocytes and neutro- 
phils on one hand and fibroblasts on the other emphasize the 
complexity of interactions between cells and chemoattractants. 
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Each cell type needs to be investigated over a  wide range of 
concentrations before concluding whether or not the cells will 
respond to a potential chemoattractant. 
PF4 antigen rapidly permeates into blood vessel wails fol- 
lowing  endothelial  injury  (18).  Whether  PF4  is  subject  to 
proteolytic cleavage in the vessel wall is not clear, however, it 
is possible that PF4-derived peptides may retain chemotactic 
activity. Indeed, we recently demonstrated that the carboxyl 
terminal 13 amino acid residues of PF4 fully express monocyte 
chemotactic activity of intact PF4, strongly suggesting that this 
tridecapeptide contains the chemotactically active site of PF4 
(19).  Release of this peptide by proteolysis in the tissues could 
provide locally a  potent chemotactic agent for inflammatory 
cells. 
The function of BTG heretofore has not been described. The 
finding that BTG is highly chemotactic for fibroblasts provides 
one potentially important function for this protein. BTG shares 
marked amino acid sequence homology with PF4 (20). Despite 
close similarity in structure, as well as similarities in concentra- 
tion within the  platelet and  in  the  quantity of each protein 
released from stimulated platelets (21),  however,  there are a 
number of differences between BTG and PF4. PF4 does not 
compete with BTG for receptor binding on endothelial cells 
(22),  an observation suggesting that BTG and PF4 may utilize 
different receptors in promoting fibroblast chemotaxis. Also, 
BTG has a longer half-time in the circulation (21),  suggesting 
that BTG may function effectively as a chemoattractant over 
a longer time. In the experiments reported above, on a mole to 
mole basis, BTG is a more potent fibroblast chemoattractant 
than PF4. The maximum effect of BTG occurs at 1.7 x  10  -~° 
M,  30-fold less than  the  concentration  required for optimal 
effectiveness of PF4. 
Recently, PDGF was shown to have fibroblast chemotactic 
activity (5). In that work, in which the concentrations of PDGF 
were expressed as units of mitogenic activity, the dose-response 
curves for the mitogenic and chemotactic activities of PDGF 
were found to be similar up to the optimal concentration for 
chemotactic activity. Above that  concentration,  chemotactic 
activity declined while mitogenic activity persisted. We now 
demonstrate  that  PDGF  is  at  least  as  potent  a  fibroblast 
chemoattractant as fibronectin and that the maximal chemo- 
tactic  activity  occurs  at  10 -9  M,  a  concentration  virtually 
identical to the dissociation constant (0.7  x  l0  -9 M) of PDGF 
we reported in studies of its binding to fibroblasts (10).  The fibroblast chemotactic activity of PDGF  is likely due  to  an 
interaction of PDGF with specific cell surface receptors. Such 
receptors have been suggested in direct binding studies with 
mouse  fibroblasts,  human  skin  fibroblasts,  arterial  smooth 
muscle cells, and human glial cells (10, 23, 24). The chemotactic 
responsiveness of neutrophils and  monocytes to  PDGF  also 
suggests that these cells have receptors for PDGF (3). PDGF 
I and PDGF II show comparable chemotactic activity, analo- 
gous to the finding that both proteins have similar mitogenic 
activity (7). 
The demonstration of PDGF fibroblast chemotactic activity 
by Seppa et  al.  (5)  was  preceded by their observation that 
supernatants from thrombin-stimulated platelets were chemo- 
tactic for fibroblasts. The possibility that other factors released 
by stimulated platelets besides PDGF might also have chem- 
otactic activity for fibroblasts was not examined. The present 
results indicate that at least two other proteins released from 
platelet alpha granules, PF4 and BTG, also have the capacity 
to promote fibroblast chemotaxis, and that their effects appear 
to be at least as great as the effects achieved by either PDGF 
I or PDGF II. The possibility that platelets contain still other 
chemotactic factors for fibroblasts needs further study because 
platelets release fibronectin, a  known chemoattractant for fi- 
broblasts (16), and Nakao et al. recently observed that  12-L- 
5,8,10,14-eicosatetraenoic acid, a platelet lipoxygenase product, 
produces smooth muscle migration (25).  It must be concluded 
that the role of platelets in inflammation and wound healing 
is likely to be highly complex, involving a  variety of factors 
with differing potency and cellular specificity. 
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